Cytek Biosciences, Inc. (CTKB)

Market Cap	520.35M
Revenue (ttm)	196.04M
Net Income (ttm)	-6.40M
Shares Out	127.22M
EPS (ttm)	-0.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	718,969
Open	3.980
Previous Close	3.920
Day's Range	3.970 - 4.120
52-Week Range	2.370 - 7.630
Beta	1.36
Analysts	Hold
Price Target	6.00 (+46.7%)
Earnings Date	Nov 4, 2025

About CTKB

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. The company offers aurora and northern lights systems delivers cell analysis; aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; enhanced small particle detection; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent c...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jul 23, 2021
• Employees: 648
• Stock Exchange: NASDAQ
• Ticker Symbol: CTKB
• Website: https://cytekbio.com

Financial Performance

In 2024, Cytek Biosciences's revenue was $200.45 million, an increase of 3.85% compared to the previous year's $193.02 million. Losses were -$6.02 million, -50.44% less than in 2023.

Analyst Summary

According to 4 analysts, the average rating for CTKB stock is "Hold." The 12-month stock price target is $6.0, which is an increase of 46.70% from the latest price.

Price Target

$6.0

(46.70% upside)

Analyst Consensus: Hold